156 related articles for article (PubMed ID: 36054316)
1. Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.
Pratz KW; DiNardo CD; Selleslag D; Li J; Yamamoto K; Konopleva M; Stevens D; Kantarjian H; Traina F; Venditti A; Mayer J; Montez M; Jin H; Duan Y; Brackman D; Zha J; Potluri J; Werner M; Jonas BA
Am J Hematol; 2022 Nov; 97(11):E416-E419. PubMed ID: 36054316
[No Abstract] [Full Text] [Related]
2. Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study.
Jonas BA; DiNardo C; Fracchiolla N; Pristupa A; Ishizawa K; Jin J; Konopleva M; Ofran Y; Montesinos P; Kovacsovics T; Jang JH; Kantarjian H; Duan Y; Potluri J; Werner M; Pratz KW
Am J Hematol; 2022 Nov; 97(11):E422-E425. PubMed ID: 36053878
[No Abstract] [Full Text] [Related]
3. Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax.
Niswander LM; Chung P; Diorio C; Tasian SK
Haematologica; 2023 Nov; 108(11):3142-3147. PubMed ID: 37021525
[No Abstract] [Full Text] [Related]
4. [Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].
Tian FQ; Zhang LS; Li JH; Tang MQ; Jiang J; Cheng XH; Zhang XC; Jiang M
Zhonghua Xue Ye Xue Za Zhi; 2020 Aug; 41(8):694-696. PubMed ID: 32942828
[No Abstract] [Full Text] [Related]
5. Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.
Zappasodi P; Brociner M; Merati G; Nizzoli ME; Roncoroni E; Boveri E; Castagnola C; Arcaini L
Ann Hematol; 2021 Apr; 100(4):1111-1113. PubMed ID: 33175198
[No Abstract] [Full Text] [Related]
6. [Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].
Zong LH; Wu XX; Zhang J; Li MY; Song BQ; Kong JY; Kong X; Hu XH; Bao XB; Qiu HY; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):861-864. PubMed ID: 34788928
[No Abstract] [Full Text] [Related]
7. Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE-A.
Gangat N; Tefferi A
Am J Hematol; 2024 Apr; 99(4):515-518. PubMed ID: 38375926
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study.
Lou Y; Shao L; Mao L; Lu Y; Ma Y; Fan C; Jiang H; Li J; Jin J
Leuk Res; 2020 Apr; 91():106317. PubMed ID: 32092584
[No Abstract] [Full Text] [Related]
9. Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
Yamamoto K; Shinagawa A; DiNardo CD; Pratz KW; Ishizawa K; Miyamoto T; Komatsu N; Nakashima Y; Yoshida C; Fukuhara N; Usuki K; Yamauchi T; Asada N; Asou N; Choi I; Miyazaki Y; Honda H; Okubo S; Kurokawa M; Zhou Y; Zha J; Potluri J; Matsumura I
Jpn J Clin Oncol; 2022 Jan; 52(1):29-38. PubMed ID: 34739075
[TBL] [Abstract][Full Text] [Related]
10. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
11. [Durable molecular remission in a patient with relapsed NPM1/IDH1 mutant acute myeloid leukemia treated with venetoclax combined with azacitidine: a case report].
Liu XH; Wu Y; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):166. PubMed ID: 35381683
[No Abstract] [Full Text] [Related]
12. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
Pratz KW; Jonas BA; Pullarkat V; Thirman MJ; Garcia JS; Döhner H; Récher C; Fiedler W; Yamamoto K; Wang J; Yoon SS; Wolach O; Yeh SP; Leber B; Esteve J; Mayer J; Porkka K; Illés Á; Lemoli RM; Turgut M; Ku G; Miller C; Zhou Y; Zhang M; Chyla B; Potluri J; DiNardo CD
Am J Hematol; 2024 Apr; 99(4):615-624. PubMed ID: 38343151
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo drug sensitivity profiling-guided treatment of a relapsed pediatric mixed-phenotype acute leukemia with venetoclax and azacitidine.
Gonzales F; Guilmatre A; Barthélémy A; Lapillonne H; Pottier N; Leverger G; Petit A; Cheok MH
Pediatr Blood Cancer; 2022 Oct; 69(10):e29678. PubMed ID: 35353439
[No Abstract] [Full Text] [Related]
14. Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax.
Chojecki AL; Arnall J; Boselli D; Patel R; Chiad Z; DiSogra KY; Karabinos A; Chen T; Cruz A; Verbyla A; Ai J; Knight TG; Ragon BK; Shah NA; Sanikommu SR; Symanowski J; Avalos BR; Copelan EA; Grunwald MR
Leuk Res; 2022 Aug; 119():106904. PubMed ID: 35753088
[No Abstract] [Full Text] [Related]
15. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.
Venugopal S; Maiti A; DiNardo CD; Qiao W; Ning J; Loghavi S; Daver NG; Kadia TM; Rausch CR; Alvarado Y; Ohanian M; Sasaki K; Short NJ; Takahashi K; Yilmaz M; Ravandi F; Kantarjian HM; Konopleva MY
Leuk Lymphoma; 2021 Dec; 62(14):3501-3505. PubMed ID: 34474640
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia.
Patel KK; Zeidan AM; Shallis RM; Prebet T; Podoltsev N; Huntington SF
Blood Adv; 2021 Feb; 5(4):994-1002. PubMed ID: 33591323
[TBL] [Abstract][Full Text] [Related]
17. Azacitidine and Venetoclax in AML.
Moore JW; Pelcovits A; Reagan JL
N Engl J Med; 2020 Nov; 383(21):2088. PubMed ID: 33207105
[No Abstract] [Full Text] [Related]
18. Azacitidine and Venetoclax in AML.
Lucijanic M
N Engl J Med; 2020 Nov; 383(21):2087-2088. PubMed ID: 33207104
[No Abstract] [Full Text] [Related]
19. Azacitidine and Venetoclax in AML.
Chitikela S; Kumar L; Sahoo RK
N Engl J Med; 2020 Nov; 383(21):2087. PubMed ID: 33207103
[No Abstract] [Full Text] [Related]
20. The heart of VIALE-A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia.
Patel SA
Br J Haematol; 2024 Apr; 204(4):1137-1138. PubMed ID: 38339780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
